Silicon Valley TMS Now Offering Cutting Edge Mental Health Technology for Obsessive-Compulsive Disorder (OCD) in Northern California

by NASDAQ Market News March 5, 2019

NASDAQ Market News
Click here to email author

Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics

Continued ICP Orders From Japanese Customers

Ads